Nasus Pharma prices 1.25M shares at $8.00 in initial public offering

Nasus Pharma (NSRX) announced the pricing of its initial public offering of 1,250,000 ordinary shares at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10 million, prior to deducting underwriting discounts, commissions, and other offering expenses and excluding any exercise of the underwriters’ option to purchase any additional securities as described herein. In addition, Nasus Pharma has granted the underwriters an option for a period of up to 45 days from the date of the final prospectus, purchase up to an additional 187,500 Ordinary Shares at the initial public offering price, less the underwriting discounts and commissions, to cover the over-allotment, if any. The Company intends to use the net proceeds from the initial public offering for furthering the development of its intranasal Epinephrine program, including, manufacturing scale-up and additional Phase 2 studies, and the remainder for general and administrative corporate purposes, including working capital, and capital expenditures. In connection with the offering, Nasus Pharma’s Ordinary Shares have been approved for listing on the NYSE American. The Ordinary Shares are expected to begin trading on the NYSE American on August 13, 2025 under the ticker symbol “NSRX”. The offering is expected to close on August 14, 2025, subject to customary closing conditions. Laidlaw & Company and Craft Capital Management are acting as Joint Bookrunners for the offering.